COVID-19 and Venous Thromboembolism
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Vascular Medicine".
Deadline for manuscript submissions: closed (15 March 2022) | Viewed by 15814
Special Issue Editor
Interests: atherosclerosis; vascular medicine; doppler ultrasonography; atherosclerotic vascular diseases; peripheral vascular diseases; phlebology; carotid artery diseases; angiology; capillaroscopy
Special Issue Information
Dear Colleagues,
Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has become a global concern, having a universal impact on humanity. It has been established that COVID-19 may predispose patients to thrombotic events with severe impact on their prognosis. The activation of the coagulation system with thromboembolic manifestations, including deep vein thrombosis, pulmonary embolism, arterial thrombotic events, and disseminated intravascular coagulopathy (DIC), has been described in several stage of COVID-19 disease. A favorable outcome has been reported with the use of heparin in COVID-19 patients, especially in those with markedly high D-dimer levels or with sepsis-induced coagulopathy. Conversely, little is known about the role of fondaparinux and direct oral anti-coagulants (DOACs). This Special Issue of the Journal of Clinical Medicine focuses on the update of mechanism of coagulation impairment, vascular manifestations, and therapeutic antithrombotic strategies/approaches.
Dr. Luca Costanzo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- COVID-19
- SARS-CoV-2
- Thrombosis
- Inflammation
- Coagulopathy
- D-Dimer
- Low-molecular-weight heparin
- Aspirin
- DOAC
- Vaccine